Antiretroviral treatment in developing countries: the peril of neglecting private providers.
Document Type Article
This article is also available from www.bmj.com
Action is underway to increase access to antiretroviral drugs, especially in countries with high rates of HIV
The role of private providers is largely ignored, although they are an important source of care for stigmatising diseases in many poor countries
Evidence is emerging that antiretroviral drugs are leaking into formal and informal private markets
Uncontrolled use of drugs in the private sector will lead to rapid development of HIV resistance
Countries require guidance and support from international policy makers and pharmaceutical companies to implement strategies for working with private providers